WOODBRIDGE, ON, Feb. 10, 2015 /PRNewswire/ - Pivotal
Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the
"Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease and overall health,
announced today that the U.S. Patent and Trademark Office (USPTO)
has issued Patent Number 8,951,514 titled "STATIN and
Omega-3 Fatty Acids for Reduction of Apolipoprotein-B Levels" and
Patent Number 8,952,000 titled "Cholesterol Absorption
Inhibitor and Omega-3 Fatty Acids for the Reduction of Cholesterol
and for the Prevention or Reduction of Cardiovascular, Cardiac and
Vascular Events." Both of these patents cover
VASCAZEN®'s formulation in conjunction with a
Statin and Cholesterol Absorption Inhibitor respectively. These
patents have terms that expire no earlier than 2032.
"The issuance of these patents is an important milestone for the
Company as it protects our formulation in conjunction with Statins
and Cholesterol Absorption Inhibitors," said Dr. George Jackowski, Pivotal's founder and Chief
Scientific Officer. " We believe these combinations could
significantly benefit the management of cardiovascular patients
going forward beyond normalizing their lipid profile."
These issued patents are part of Pivotal's expanding patent
portfolio that protects its unique formulation. The Company has a
total of three issued patents and five (5) patent applications
currently in prosecution in the U.S. The Company is pursuing patent
applications related to VASCAZEN®'s formulation,
composition and combinations with existing cardiovascular drugs in
the U.S. and in multiple jurisdictions outside the United States.
About VASCAZEN®
VASCAZEN® is currently available in the U.S.
as a prescription-only medical food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular
patients. VASCAZEN® is a >90% pure Omega-3
with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by
a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct
an Omega-3 deficiency within eight weeks of treatment with positive
concomitant effects on the lipid profiles, mainly a 48% reduction
of triglycerides and an increase of HDL without negative impact on
the LDL-C lipid profile.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF;
CSE:PVO), specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription only
medical food formulated to meet the dietary Omega-3 deficient needs
of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical
grade Omega-3 providing over 90% pure Omega-3 in each capsule for
the maintenance of good health. OMAZEN® is a
patented product available for sale and distribution in
Canada. BeneFishial™ is the
first product in Pivotal's new nutraceutical product line, which
has been specifically designed to be sold in the OTC direct to
retail or direct to consumer markets.
Disclosure Notice
The information contained in this document is as February 10, 2015. This press release contains
forward-looking statements. Such forward-looking statements are
subject to a number of risks, assumptions and uncertainties that
could cause Pivotal's actual results to differ materially from
those projected in such forward-looking statements. These
statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause
actual results to differ materially from those in forward looking
statements include the following: Pivotal's inability to obtain
additional financing on acceptable terms; growth in costs and
expenses; inability to compete with others who provide comparable
products; risk that the Company's products will not gain widespread
market acceptance; risks relating to the Company's ability to
maintain its CSE listing. Forward-looking statements speak only as
of the date made and are not guarantees of future performance.
The Company undertakes no obligation to publicly update or
revise any forward-looking statements contained in this document as
a result of new information or future events or developments. The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.